Optimized PEGylated Bilosomes for Oral Delivery of Hesperetin: Formulation and In Vitro Evaluation in Breast Cancer

Key Points

• Effective oral delivery of hesperetin was achieved using optimized pegylated bilosomes for breast cancer.
• In vitro evaluation demonstrated significant improvements in the formulation's stability and drug release profile.
• The pegylated bilosomes enhance drug bioavailability compared to traditional delivery methods.
• Further research may explore the therapeutic effects in vivo, assessing real-world applications for breast cancer treatment.